Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment

Annemarie Shibata, Emily McMullen, Alex Pham, Michael A. Belshan, Bridget Sanford, You Zhou, Michael Goede, Abjijit A. Date, Christopher J. Destache

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The use of combination antiretroviral nanoparticles (cART NPs) was investigated as a novel treatment approach for the inhibition of HIV-1 replication. We developed nanoparticles of biodegradable polymer, poly-(dl-lactide-co-glycolic acid; PLGA) containing efavirenz (EFV) and boosted lopinavir (lopinavir/ritonavir; LPV/r) by a high-pressure homogenization method. The method resulted in >79% drug entrapment efficiency for each of the three drugs. The average size of cART NPs was 138.3±55.4 nm as measured by dynamic light scanning, confirmed by scanning electron microscopy (SEM) with an average surface charge of-13.7±4.5. Lissamine-rhodamine-labeled fluorescent PLGA NPs exhibited efficient uptake in nonimmune (HeLa cells) and immune (H9 T cells) cells as measured by confocal microscopy. Cells treated with cART NPs resulted in minimal loss of cell viability over 28 days. Subcellular fractionation studies demonstrated that HIV-1-infected H9 monocytic cells treated with cART NPs contained significantly (p50 for each of the three drugs in the cART NPs was

Original languageEnglish
Pages (from-to)746-754
Number of pages9
JournalAIDS Research and Human Retroviruses
Volume29
Issue number5
DOIs
StatePublished - 2013

Fingerprint

Drug Combinations
Nanoparticles
HIV-1
Lopinavir
glycolic acid
efavirenz
Ritonavir
Rhodamines
HeLa Cells
Confocal Microscopy
Pharmaceutical Preparations
Electron Scanning Microscopy
Cell Survival
Polymers
T-Lymphocytes
Light
Pressure

All Science Journal Classification (ASJC) codes

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment. / Shibata, Annemarie; McMullen, Emily; Pham, Alex; Belshan, Michael A.; Sanford, Bridget; Zhou, You; Goede, Michael; Date, Abjijit A.; Destache, Christopher J.

In: AIDS Research and Human Retroviruses, Vol. 29, No. 5, 2013, p. 746-754.

Research output: Contribution to journalArticle

Shibata, Annemarie ; McMullen, Emily ; Pham, Alex ; Belshan, Michael A. ; Sanford, Bridget ; Zhou, You ; Goede, Michael ; Date, Abjijit A. ; Destache, Christopher J. / Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment. In: AIDS Research and Human Retroviruses. 2013 ; Vol. 29, No. 5. pp. 746-754.
@article{5274e411078544e2b27cdf75948bb2fa,
title = "Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment",
abstract = "The use of combination antiretroviral nanoparticles (cART NPs) was investigated as a novel treatment approach for the inhibition of HIV-1 replication. We developed nanoparticles of biodegradable polymer, poly-(dl-lactide-co-glycolic acid; PLGA) containing efavirenz (EFV) and boosted lopinavir (lopinavir/ritonavir; LPV/r) by a high-pressure homogenization method. The method resulted in >79{\%} drug entrapment efficiency for each of the three drugs. The average size of cART NPs was 138.3±55.4 nm as measured by dynamic light scanning, confirmed by scanning electron microscopy (SEM) with an average surface charge of-13.7±4.5. Lissamine-rhodamine-labeled fluorescent PLGA NPs exhibited efficient uptake in nonimmune (HeLa cells) and immune (H9 T cells) cells as measured by confocal microscopy. Cells treated with cART NPs resulted in minimal loss of cell viability over 28 days. Subcellular fractionation studies demonstrated that HIV-1-infected H9 monocytic cells treated with cART NPs contained significantly (p50 for each of the three drugs in the cART NPs was",
author = "Annemarie Shibata and Emily McMullen and Alex Pham and Belshan, {Michael A.} and Bridget Sanford and You Zhou and Michael Goede and Date, {Abjijit A.} and Destache, {Christopher J.}",
year = "2013",
doi = "10.1089/aid.2012.0301",
language = "English",
volume = "29",
pages = "746--754",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment

AU - Shibata, Annemarie

AU - McMullen, Emily

AU - Pham, Alex

AU - Belshan, Michael A.

AU - Sanford, Bridget

AU - Zhou, You

AU - Goede, Michael

AU - Date, Abjijit A.

AU - Destache, Christopher J.

PY - 2013

Y1 - 2013

N2 - The use of combination antiretroviral nanoparticles (cART NPs) was investigated as a novel treatment approach for the inhibition of HIV-1 replication. We developed nanoparticles of biodegradable polymer, poly-(dl-lactide-co-glycolic acid; PLGA) containing efavirenz (EFV) and boosted lopinavir (lopinavir/ritonavir; LPV/r) by a high-pressure homogenization method. The method resulted in >79% drug entrapment efficiency for each of the three drugs. The average size of cART NPs was 138.3±55.4 nm as measured by dynamic light scanning, confirmed by scanning electron microscopy (SEM) with an average surface charge of-13.7±4.5. Lissamine-rhodamine-labeled fluorescent PLGA NPs exhibited efficient uptake in nonimmune (HeLa cells) and immune (H9 T cells) cells as measured by confocal microscopy. Cells treated with cART NPs resulted in minimal loss of cell viability over 28 days. Subcellular fractionation studies demonstrated that HIV-1-infected H9 monocytic cells treated with cART NPs contained significantly (p50 for each of the three drugs in the cART NPs was

AB - The use of combination antiretroviral nanoparticles (cART NPs) was investigated as a novel treatment approach for the inhibition of HIV-1 replication. We developed nanoparticles of biodegradable polymer, poly-(dl-lactide-co-glycolic acid; PLGA) containing efavirenz (EFV) and boosted lopinavir (lopinavir/ritonavir; LPV/r) by a high-pressure homogenization method. The method resulted in >79% drug entrapment efficiency for each of the three drugs. The average size of cART NPs was 138.3±55.4 nm as measured by dynamic light scanning, confirmed by scanning electron microscopy (SEM) with an average surface charge of-13.7±4.5. Lissamine-rhodamine-labeled fluorescent PLGA NPs exhibited efficient uptake in nonimmune (HeLa cells) and immune (H9 T cells) cells as measured by confocal microscopy. Cells treated with cART NPs resulted in minimal loss of cell viability over 28 days. Subcellular fractionation studies demonstrated that HIV-1-infected H9 monocytic cells treated with cART NPs contained significantly (p50 for each of the three drugs in the cART NPs was

UR - http://www.scopus.com/inward/record.url?scp=84876909626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876909626&partnerID=8YFLogxK

U2 - 10.1089/aid.2012.0301

DO - 10.1089/aid.2012.0301

M3 - Article

VL - 29

SP - 746

EP - 754

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 5

ER -